Mutational/JJ
Analysis/NN
of/IN
Extranodal/JJ
NK/T-Cell/NN
Lymphoma/NN
Using/VBG
Targeted/VBN
Sequencing/NN
with/IN
a/DT
Comprehensive/JJ
Cancer/NN
Panel/NN
./.
====================
Extranodal/JJ
natural/JJ
killer/NN
(/(
NK/NN
)/)
/T-cell/NN
lymphoma/NN
,/,
nasal/JJ
type/NN
(/(
NKTCL/NN
)/)
,/,
is/VBZ
a/DT
malignant/JJ
disorder/NN
of/IN
cytotoxic/JJ
lymphocytes/NNS
of/IN
NK/NN
or/CC
T/NN
cells/NNS
./.
====================
It/PRP
is/VBZ
an/DT
aggressive/JJ
neoplasm/NN
with/IN
a/DT
very/RB
poor/JJ
prognosis/NN
./.
====================
Although/IN
extranodal/JJ
NKTCL/NN
reportedly/RB
has/VBZ
a/DT
strong/JJ
association/NN
with/IN
Epstein-Barr/JJ
virus/NN
,/,
the/DT
molecular/JJ
pathogenesis/NN
of/IN
NKTCL/NN
has/VBZ
been/VBN
unexplored/VBN
./.
====================
The/DT
recent/JJ
technological/JJ
advancements/NNS
in/IN
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
have/VBP
made/VBN
DNA/NN
sequencing/NN
cost-/JJ
and/CC
time-effective/JJ
,/,
with/IN
more/RBR
reliable/JJ
results/NNS
./.
====================
Using/VBG
the/DT
Ion/NN
Proton/JJ
Comprehensive/JJ
Cancer/NN
Panel/NN
,/,
we/PRP
sequenced/VBD
409/CD
cancer-related/JJ
genes/NNS
to/TO
identify/VB
somatic/JJ
mutations/NNS
in/IN
five/CD
NKTCL/NN
tissue/NN
samples/NNS
./.
====================
The/DT
sequencing/NN
analysis/NN
detected/VBD
25/CD
mutations/NNS
in/IN
21/CD
genes/NNS
./.
====================
Among/IN
them/PRP
,/,
KMT2D/NN
,/,
a/DT
histone/NN
modification-related/JJ
gene/NN
,/,
was/VBD
the/DT
most/JJS
frequently/RB
mutated/VBN
gene/NN
(/(
four/CD
of/IN
the/DT
five/CD
cases/NNS
)/)
./.
====================
This/DT
result/NN
was/VBD
consistent/JJ
with/IN
recent/JJ
NGS/NN
studies/NNS
that/IN
have/VBP
suggested/VBN
KMT2D/NN
as/IN
a/DT
novel/JJ
driver/RB
gene/NN
in/IN
NKTCL/NN
./.
====================
Mutations/NNS
were/VBD
also/RB
found/VBD
in/IN
ARID1A/NN
,/,
a/DT
chromatin/NN
remodeling/NN
gene/NN
,/,
and/CC
TP53/NN
,/,
which/WDT
also/RB
recurred/VBD
in/IN
recent/JJ
NGS/NN
studies/NNS
./.
====================
We/PRP
also/RB
found/VBD
mutations/NNS
in/IN
18/CD
novel/JJ
candidate/NN
genes/NNS
,/,
with/IN
molecular/JJ
functions/NNS
that/IN
were/VBD
potentially/RB
implicated/VBN
in/IN
cancer/NN
development/NN
./.
====================
We/PRP
suggest/VBP
that/IN
these/DT
genes/NNS
may/MD
result/VB
in/IN
multiple/JJ
oncogenic/JJ
events/NNS
and/CC
may/MD
be/VB
used/VBN
as/IN
potential/JJ
bio-markers/NNS
of/IN
NKTCL/NN
in/IN
the/DT
future/JJ
./.
====================
Extranodal/JJ
natural/JJ
killer/NN
(/(
NK/NN
)/)
/T-cell/NN
lymphoma/NN
,/,
nasal/JJ
type/NN
(/(
NKTCL/NN
)/)
is/VBZ
a/DT
malignant/JJ
neoplasm/NN
characterized/VBN
by/IN
a/DT
cytotoxic/JJ
phenotype/NN
and/CC
is/VBZ
associated/VBN
with/IN
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
infection/NN
./.
====================
It/PRP
is/VBZ
rare/JJ
in/IN
Western/NN
countries/NNS
but/CC
is/VBZ
the/DT
most/JJS
common/JJ
subtype/NN
of/IN
mature/JJ
T/NN
and/CC
NK/NN
cell/NN
neoplasms/NNS
in/IN
Asia/NN
[/(
1/CD
]/)
./.
====================
Although/IN
it/PRP
has/VBZ
been/VBN
suggested/VBN
that/IN
EBV/NN
could/MD
play/VB
a/DT
pathogenic/JJ
role/NN
in/IN
the/DT
development/NN
of/IN
NKTCL/NN
,/,
its/PRP$
etiology/NN
and/CC
molecular/JJ
pathogenesis/NN
have/VBP
remained/VBN
unexplained/JJ
./.
====================
The/DT
clinical/JJ
course/NN
of/IN
NKTCL/NN
is/VBZ
usually/RB
highly/RB
aggressive/JJ
,/,
but/CC
its/PRP$
survival/NN
rate/NN
has/VBZ
improved/VBN
with/IN
the/DT
recent/JJ
progress/VBP
in/IN
intensive/JJ
therapies/NNS
,/,
including/VBG
combined/JJ
chemoradiotherapy/NN
and/CC
autologous/JJ
bone/NN
marrow/NN
transplantation/NN
[/(
23/CD
]/)
./.
====================
However/RB
,/,
the/DT
prognosis/NN
of/IN
NKTCL/NN
is/VBZ
variable/JJ
,/,
and/CC
the/DT
recurrence/NN
rate/NN
is/VBZ
still/RB
high/JJ
./.
====================
Thus/RB
,/,
there/EX
is/VBZ
a/DT
great/JJ
need/NN
to/TO
define/VB
a/DT
molecular/JJ
pathway/NN
associated/VBN
with/IN
the/DT
pathogenesis/NN
,/,
prognosis/NN
,/,
or/CC
drug/NN
resistance/NN
of/IN
NKTCL/NN
./.
====================
Next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
has/VBZ
made/VBN
genetic/JJ
and/CC
molecular/JJ
studies/NNS
effective/JJ
,/,
with/IN
more/RBR
reliable/JJ
results/NNS
achieved/VBD
[/(
4/CD
]/)
./.
====================
High-throughput/JJ
sequencing/NN
technology/NN
can/MD
conduct/VB
millions/NNS
of/IN
sequencing/NN
reactions/NNS
in/IN
parallel/NN
./.
====================
Unlike/IN
in/IN
Sanger/NN
sequencing/NN
,/,
NGS/NN
enables/VBZ
the/DT
detection/NN
of/IN
novel/JJ
genetic/JJ
alterations/NNS
,/,
since/IN
the/DT
sequence/NN
of/IN
every/DT
base/NN
in/IN
the/DT
region/NN
of/IN
interest/JJ
is/VBZ
detected/VBN
,/,
and/CC
a/DT
large/JJ
number/NN
of/IN
loci/NNS
of/IN
interest/JJ
(/(
multiple/JJ
genes/NNS
)/)
can/MD
be/VB
analyzed/VBN
in/IN
a/DT
single/JJ
panel/NN
./.
====================
It/PRP
is/VBZ
currently/RB
used/VBN
in/IN
a/DT
wide/JJ
variety/NN
of/IN
research/NN
fields/NNS
./.
====================
For/IN
example/NN
,/,
it/PRP
has/VBZ
been/VBN
used/VBN
to/TO
identify/VB
mutations/NNS
or/CC
to/TO
profile/VB
gene/NN
expressions/NNS
in/IN
cancer/NN
research/NN
and/CC
has/VBZ
been/VBN
utilized/VBN
in/IN
population/NN
genomic/JJ
studies/NNS
,/,
including/VBG
the/DT
1000/CD
Genomes/NNS
Project/JJ
./.
====================
Recent/JJ
advancements/NNS
in/IN
NGS/NN
technology/NN
have/VBP
revolutionized/VBN
clinical/JJ
research/NN
./.
====================
Moreover/RB
,/,
the/DT
emergence/NN
of/IN
bench-top/JJ
sequencers/NNS
,/,
such/JJ
as/IN
the/DT
Ion/NN
Proton/JJ
platform/NN
,/,
has/VBZ
allowed/VBN
genomic/JJ
and/CC
molecular/JJ
studies/NNS
to/TO
be/VB
done/VBN
easily/RB
and/CC
effectively/RB
by/IN
individual/JJ
researchers/NNS
and/CC
institutes/NNS
./.
====================
Nowadays/NNS
,/,
many/JJ
molecular/JJ
studies/NNS
on/IN
the/DT
cancer/NN
genome/NN
are/VBP
being/VBG
performed/VBN
using/VBG
NGS/NN
./.
====================
The/DT
detection/NN
of/IN
mutations/NNS
or/CC
gene/NN
expression/NN
in/IN
mixed/JJ
samples/NNS
requires/VBZ
high/JJ
sequencing/NN
depth/NN
,/,
which/WDT
is/VBZ
not/RB
achieved/VBN
by/IN
whole-genome/JJ
``/CD
shotgun/JJ
''/CD
approaches/NNS
./.
====================
Targeted/VBN
sequencing/NN
is/VBZ
able/JJ
to/TO
yield/VB
a/DT
desirable/JJ
sequencing/NN
depth/NN
for/IN
this/DT
purpose/NN
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
more/RBR
efficient/JJ
to/TO
identify/VB
mutations/NNS
correlating/VBG
with/IN
tumor/NN
phenotype/NN
and/CC
in/IN
developing/VBG
possible/JJ
targeted/VBN
drug/NN
therapies/NNS
./.
====================
Yet/RB
,/,
molecular/JJ
studies/NNS
using/VBG
NGS/NN
in/IN
NKTCL/NN
have/VBP
languished/VBN
compared/VBN
with/IN
B-cell/NN
lymphoma/NN
cases/NNS
[/(
56789/CD
]/)
./.
====================
Therefore/RB
,/,
this/DT
study/NN
aims/VBZ
to/TO
identify/VB
mutations/NNS
possibly/RB
responsible/JJ
for/IN
NKTCL/NN
using/VBG
targeted/VBN
sequencing/NN
with/IN
a/DT
comprehensive/JJ
panel/NN
of/IN
409/CD
cancer-related/JJ
genes/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
and/CC
to/TO
suggest/VB
candidate/NN
genes/NNS
that/WDT
can/MD
be/VB
used/VBN
as/IN
potential/JJ
bio-markers/NNS
of/IN
NKTCL/NN
in/IN
the/DT
future/JJ
./.
====================
Clinical/JJ
information/NN
====================
Samples/NNS
from/IN
tumors/NNS
diagnosed/VBD
between/IN
2011/CD
and/CC
2014/CD
were/VBD
collected/VBN
from/IN
Dankook/NN
University/NN
Hospital/JJ
(/(
Cheonan/NNP
)/)
in/IN
South/NN
Korea/NN
./.
====================
Five/CD
formalin-fixed/JJ
and/CC
paraffin-embedded/JJ
(/(
FFPE/NN
)/)
tumor/NN
samples/NNS
from/IN
NKTCL/NN
were/VBD
analyzed/VBN
./.
====================
NKTCL/NN
was/VBD
diagnosed/VBN
according/VBG
to/TO
the/DT
2008/CD
World/NN
Health/NN
Organization/NN
classification/NN
[/(
10/CD
]/)
./.
====================
In/IN
all/DT
cases/NNS
,/,
immunohistochemical/JJ
studies/NNS
for/IN
CD3/NN
,/,
CD56/NN
,/,
and/CC
granzyme/NN
B/NN
,/,
as/IN
well/RB
as/IN
EBV-encoded/JJ
small/JJ
RNA/NN
in/IN
situ/FW
hybridization/NN
,/,
were/VBD
carried/VBN
out/RP
with/IN
the/DT
FFPE/NN
tissues/NNS
./.
====================
All/DT
immunohistochemical/JJ
results/NNS
were/VBD
positive/JJ
for/IN
the/DT
markers/NNS
,/,
but/CC
one/CD
case/NN
was/VBD
negative/JJ
for/IN
EBV/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Patient/JJ
ages/NNS
ranged/VBD
from/IN
46/CD
to/TO
80/CD
years/NNS
./.
====================
One/CD
case/NN
was/VBD
from/IN
the/DT
submandibular/JJ
region/NN
./.
====================
The/DT
remainder/NN
was/VBD
from/IN
the/DT
nasal/JJ
cavity/NN
./.
====================
Supplementary/JJ
Table/JJ
1/CD
summarizes/VBZ
the/DT
information/NN
of/IN
the/DT
enrolled/JJ
subjects/NNS
./.
====================
DNA/NN
preparation/NN
====================
FFPE/NN
tissue/NN
samples/NNS
were/VBD
deparaffinized/VBN
in/IN
xylene/NN
,/,
and/CC
3-to/RB
5-mm/NN
thick/JJ
sections/NNS
were/VBD
extracted/VBN
from/IN
the/DT
samples/NNS
./.
====================
Using/VBG
the/DT
QIAamp/NN
DNA/NN
Mini/NN
Kit/NN
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
,/,
we/PRP
isolated/VBD
genomic/JJ
DNA/NN
from/IN
the/DT
samples/NNS
following/VBG
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
The/DT
quality/NN
control/NN
results/NNS
of/IN
the/DT
DNA/NN
preparations/NNS
are/VBP
illustrated/VBN
in/IN
Supplementary/JJ
Table/JJ
2/CD
and/CC
Supplementary/JJ
Fig/NN
./.
====================
3/CD
./.
====================
Library/JJ
preparation/NN
and/CC
Ion/NN
Proton/NN
sequencing/NN
====================
Targeted/VBN
gene/NN
sequencing/NN
was/VBD
performed/VBN
as/IN
previously/RB
described/VBN
[/(
11/CD
]/)
./.
====================
Ten/CD
nanograms/NNS
of/IN
the/DT
DNA/NN
preparations/NNS
was/VBD
used/VBN
as/IN
a/DT
template/JJ
for/IN
multiplex/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
of/IN
a/DT
409-gene/JJ
panel/NN
covering/VBG
coding/VBG
regions/NNS
(/(
Ion/NN
AmpliSeq/NN
Comprehensive/JJ
Cancer/NN
Panel/NN
;/:
Life/NNP
Technologies/NNS
,/,
Grand/CC
Island/CC
,/,
NY/NN
,/,
USA/NNP
)/)
./.
====================
Fragment/JJ
libraries/NNS
were/VBD
constructed/VBN
by/IN
DNA/NN
fragmentation/NN
,/,
barcode/RB
and/CC
adaptor/NN
ligation/NN
,/,
and/CC
library/NN
amplification/NN
using/VBG
the/DT
Ion/NN
DNA/NN
Barcoding/NN
kit/NN
(/(
Life/NN
Technologies/NNS
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
The/DT
size/NN
distribution/NN
of/IN
the/DT
DNA/NN
fragments/NNS
was/VBD
analyzed/VBN
using/VBG
a/DT
bioanalyzer/JJ
and/CC
the/DT
High/JJ
Sensitivity/NN
kit/NN
(/(
Agilent/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
Using/VBG
the/DT
Ion/NN
Xpress/NN
Template/JJ
kit/NN
(/(
Life/NN
Technologies/NNS
)/)
,/,
we/PRP
performed/VBD
template/NN
preparation/NN
,/,
emulsion/NN
PCR/NN
,/,
and/CC
Ion/NN
Sphere/JJ
Particle/NN
(/(
ISP/NN
)/)
enrichment/JJ
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
The/DT
ISPs/NNS
were/VBD
loaded/VBN
onto/IN
a/DT
P1/NN
chip/NN
and/CC
sequenced/VBN
using/VBG
an/DT
Ion/NN
P1/NN
sequencing/NN
kit/NN
(/(
Life/NN
Technologies/NNS
)/)
./.
====================
Variant/JJ
calling/JJ
and/CC
annotation/NN
====================
Ion/NN
Proton/JJ
platform-specific/JJ
pipeline/NN
software/RB
(/(
Proton/JJ
Suite/JJ
v4.4/CD
;/:
Life/NNP
Technologies/NNS
)/)
was/VBD
used/VBN
to/TO
separate/VB
the/DT
barcoded/JJ
reads/VBZ
,/,
generate/VBP
sequence/NN
alignments/NNS
with/IN
the/DT
hg19/NN
human/JJ
genome/NN
reference/VBP
,/,
perform/VBP
target-region/NN
coverage/NN
analysis/NN
,/,
and/CC
filter/NN
poor/JJ
signal/NN
reads/VBZ
./.
====================
Initial/JJ
variant/JJ
calls/NNS
were/VBD
generated/VBN
using/VBG
Proton/JJ
Suite/NN
with/IN
a/DT
plug-in/JJ
program/NN
(/(
variant/JJ
caller/NN
v4.4/CD
)/)
./.
====================
Variant/JJ
calls/NNS
were/VBD
further/RB
analyzed/VBD
using/VBG
internally/RB
developed/VBD
software/JJ
that/DT
allows/VBZ
variant/JJ
filtering/VBG
and/CC
annotation/NN
using/VBG
refGene/JJ
in/IN
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
(/(
UCSC/NN
)/)
,/,
1000/CD
Genomes/NNS
,/,
COSMIC/NN
v.67/CD
,/,
dbSNP/NN
build/JJ
138/CD
,/,
and/CC
ExAC/NN
./.
====================
To/TO
minimize/VB
false/VBP
positives/VBZ
,/,
variants/NNS
were/VBD
filtered/VBN
with/IN
a/DT
normal/JJ
population/NN
variant/JJ
database/NN
,/,
The/DT
Korean/JJ
Personal/JJ
Genome/NN
Project/JJ
(/(
http/NN
:/:
//opengenome.net//JJ
)/)
[/(
12/CD
]/)
./.
====================
Candidate/NN
variant/JJ
detection/NN
(/(
variant/JJ
filtering/NN
)/)
====================
To/TO
filter/RBR
out/IN
false-positives/VBZ
,/,
which/WDT
were/VBD
hardly/RB
regarded/VBN
as/IN
true/JJ
somatic/JJ
mutations/NNS
or/CC
disease/NN
driver/RB
mutations/NNS
,/,
we/PRP
used/VBD
several/JJ
additional/JJ
filtering/VBG
steps/NNS
that/IN
are/VBP
generally/RB
accepted/VBN
and/CC
generated/VBD
the/DT
final/JJ
variant/JJ
calls/NNS
,/,
as/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
They/PRP
included/VBD
(/(
1/LS
)/)
transition-type/JJ
point/RB
mutation/NN
;/:
(/(
2/CD
)/)
indel/RB
>/JJR
2/CD
bp/NN
;/:
(/(
3/LS
)/)
normal/JJ
variants/NNS
of/IN
Inhouse/JJ
,/,
1000/CD
Genomes/NNS
Project/JJ
,/,
and/CC
ExAC_est_Asia/NN
(/(
Broad/JJ
Institute/RB
)/)
;/:
(/(
4/CD
)/)
homozygous-type/JJ
mutation/NN
;/:
(/(
5/CD
)/)
conservation/NN
</JJR
0.3/CD
;/:
(/(
6/CD
)/)
regions/NNS
except/IN
for/IN
missense/JJ
,/,
splice/RB
site/NN
,/,
stop/RB
gained/VBN
,/,
and/CC
frameshift/NN
;/:
(/(
7/CD
)/)
total/JJ
depth/NN
</JJR
100/CD
;/:
and/CC
(/(
8/CD
)/)
altered/JJ
allele/NN
frequency/NN
>/JJR
0.3/CD
or/CC
</JJR
0.05/CD
[/(
13/CD
]/)
./.
====================
Variant/JJ
interpretation/NN
====================
To/TO
evaluate/VB
which/WDT
mutation/NN
could/MD
be/VB
actionable/JJ
or/CC
those/DT
to/TO
prioritize/VB
,/,
a/DT
literature/NN
review/NN
was/VBD
done/VBN
,/,
as/IN
was/VBD
a/DT
search/NN
for/IN
gene/NN
function/NN
,/,
in/IN
some/DT
online/JJ
databases/NNS
and/CC
gene/NN
ontology/NN
analyses/NNS
[/(
141516171819/CD
]/)
./.
====================
Sanger/NN
sequencing/NN
====================
To/TO
validate/VB
candidate/NN
loci/NNS
,/,
we/PRP
conducted/VBD
PCR/NN
amplification/NN
and/CC
Sanger/NN
sequencing/NN
./.
====================
A/DT
primer/NN
pair/NN
for/IN
the/DT
PCR/NN
amplification/NN
was/VBD
designed/VBN
in/IN
the/DT
flanking/JJ
region/NN
of/IN
each/DT
target/NN
locus/NN
using/VBG
OligoCalc/JJ
(/(
http/NN
:/:
//www.basic.northwestern.edu/biotools/oligocalc.html/NN
)/)
and/CC
Oligo/JJ
Analysis/NN
Tools/NNS
(/(
http/NN
:/:
//www.operon.com/tools/oligo-analysis-tool.aspx/JJ
)/)
./.
====================
Detailed/JJ
information/NN
on/IN
the/DT
primers/NNS
is/VBZ
summarized/VBN
in/IN
Supplementary/JJ
Table/JJ
3/CD
./.
====================
PCR/NN
was/VBD
performed/VBN
in/IN
20/CD
µL/NN
of/IN
the/DT
reaction/NN
mixture/NN
,/,
including/VBG
10/CD
µL/NN
of/IN
2×/CD
EF-Taq/NN
Pre/JJ
mix4/NN
(/(
Biofact/NNP
,/,
Daejeon/NN
,/,
Korea/NN
)/)
,/,
10/CD
µM/NN
of/IN
oligonucleotide/JJ
primers/NNS
,/,
1/CD
µL/NN
of/IN
template/JJ
,/,
and/CC
nuclease-free/JJ
water/NN
./.
====================
PCR/NN
was/VBD
carried/VBN
out/RP
as/IN
follows/VBZ
:/:
first/JJ
denaturation/NN
step/NN
of/IN
3/CD
min/NN
at/IN
95℃/CD
,/,
followed/VBN
by/IN
25/CD
cycles/NNS
of/IN
30/CD
s/NNS
at/IN
95℃/CD
,/,
annealing/VBG
of/IN
30/CD
s/NNS
at/IN
optimal/JJ
temperature/NN
,/,
extension/NN
of/IN
40/CD
s/NNS
to/TO
1/CD
min/NN
depending/VBG
on/IN
PCR/NN
product/NN
size/NN
at/IN
72℃/CD
,/,
and/CC
a/DT
final/JJ
extension/NN
for/IN
2/CD
min/NN
at/IN
72℃/CD
./.
====================
PCR/NN
products/NNS
were/VBD
confirmed/VBN
by/IN
gel/NN
electrophoresis/NN
and/CC
purified/VBN
with/IN
a/DT
PCR/NN
purification/NN
kit/NN
(/(
Favorgen/NN
Biotech/NNP
Corp./NN
,/,
Pingtung/NN
Country/NN
,/,
Taiwan/JJ
)/)
./.
====================
Products/NNS
were/VBD
sequenced/VBN
using/VBG
an/DT
ABI3500/CD
genetic/JJ
analyzer/NN
(/(
Thermo/NN
Fisher/RB
Scientific/JJ
,/,
Pittsburgh/NN
,/,
PA/NN
,/,
USA/NN
)/)
./.
====================
Sequencing/NN
data/NNS
were/VBD
aligned/VBN
with/IN
exome/JJ
sequencing/NN
data/NNS
by/IN
the/DT
Bioedit/NN
program/NN
./.
====================
Sequencing/NN
data/NNS
and/CC
mapping/NN
statistics/NNS
====================
Supplementary/JJ
Table/JJ
4/CD
summarizes/VBZ
the/DT
sequencing/NN
data/NNS
and/CC
mapping/NN
statistics/NNS
./.
====================
The/DT
length/NN
of/IN
the/DT
target/NN
regions/NNS
(/(
base/NN
pairs/NNS
,/,
bp/NN
)/)
corresponding/VBG
to/TO
the/DT
409/CD
genes/NNS
was/VBD
1,688,650/CD
bp/NN
./.
====================
The/DT
total/JJ
number/NN
of/IN
mapped/VBN
reads/VBZ
was/VBD
23,172,100/CD
,/,
and/CC
the/DT
average/NN
depth/NN
of/IN
coverage/NN
was/VBD
1,432×/CD
./.
====================
Variant/JJ
types/NNS
,/,
regions/NNS
,/,
and/CC
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
variant/JJ
forms/NNS
of/IN
each/DT
sample/NN
are/VBP
shown/VBN
in/IN
Supplementary/JJ
Table/JJ
5/CD
and/CC
Supplementary/JJ
Figs/NNS
./.
====================
4/CD
and/CC
5/CD
,/,
respectively/RB
./.
====================
A/DT
total/JJ
of/IN
7,314/CD
variants/NNS
were/VBD
detected/VBN
in/IN
the/DT
five/CD
samples/NNS
,/,
and/CC
the/DT
number/NN
of/IN
variants/NNS
identified/VBD
in/IN
each/DT
sample/NN
ranged/VBD
from/IN
881/CD
to/TO
4,099/CD
./.
====================
As/IN
shown/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
5/CD
,/,
most/JJS
of/IN
the/DT
SNPs/NNS
were/VBD
transition-type/JJ
(/(
6,344/CD
out/RP
of/IN
a/DT
total/JJ
of/IN
7,314/CD
variants/NNS
)/)
./.
====================
As/IN
a/DT
result/NN
of/IN
the/DT
filtering/JJ
steps/NNS
described/VBN
above/IN
,/,
22/CD
variants/NNS
in/IN
25/CD
loci/NNS
were/VBD
detected/VBN
(/(
Table/JJ
1/CD
)/)
./.
====================
All/DT
cases/NNS
showed/VBD
one/CD
(/(
case/NN
No/DT
./.
====================
3/CD
)/)
to/TO
14/CD
variants/NNS
(/(
case/NN
No/DT
./.
====================
2/CD
)/)
./.
====================
The/DT
lysine/NN
[/(
K/NN
]/)
-specific/JJ
methyltransferase/NN
2D/NN
(/(
KMT2D/NN
)/)
gene/NN
showed/VBD
the/DT
identical/JJ
SNP/NN
variant/JJ
(/(
missense/NN
mutation/NN
)/)
in/IN
four/CD
samples/NNS
(/(
cases/NNS
Nos/NNS
./.
====================
2/CD
,/,
3/CD
,/,
4/CD
,/,
and/CC
5/CD
)/)
./.
====================
Two/CD
different/JJ
variants/NNS
for/IN
the/DT
MYH9/NN
gene/NN
were/VBD
identified/VBN
in/IN
one/CD
sample/NN
(/(
case/NN
No/DT
./.
====================
2/CD
)/)
./.
====================
Most/JJS
of/IN
the/DT
variants/NNS
were/VBD
missense/NN
mutations/NNS
,/,
except/IN
for/IN
two/CD
stop/NN
gained/VBN
variants/NNS
for/IN
ATR/NN
and/CC
MBD1/NN
and/CC
one/CD
frameshift/NN
variant/JJ
for/IN
FLT4/NN
./.
====================
Variant/JJ
interpretation/NN
====================
The/DT
genes/NNS
were/VBD
classified/VBN
into/IN
two/CD
groups/NNS
:/:
likely/JJ
actionable/JJ
and/CC
unknown/JJ
significance/NN
./.
====================
The/DT
likely/JJ
actionable/JJ
group/NN
was/VBD
confined/VBN
to/TO
the/DT
genes/NNS
with/IN
a/DT
mutation/NN
in/IN
NKTCL/NN
,/,
which/WDT
has/VBZ
previously/RB
and/CC
recurrently/RB
been/VBN
identified/VBN
./.
====================
Three/CD
genes/NNS
were/VBD
classified/VBN
as/IN
likely/JJ
actionable/JJ
:/:
KMT2D/NN
,/,
AT-rich/JJ
interactive/JJ
domain-containing/JJ
protein/NN
1A/NN
(/(
ARID1A/NN
)/)
,/,
and/CC
TP53/NN
./.
====================
The/DT
other/JJ
group/NN
was/VBD
classified/VBN
as/IN
the/DT
unknown/JJ
significance/NN
groupivarious/JJ
functions/NNS
can/MD
be/VB
present/JJ
,/,
with/IN
molecular/JJ
function/NN
potentially/RB
implied/VBD
in/IN
cancer/NN
development/NN
./.
====================
The/DT
variant/JJ
interpretation/NN
results/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
2/CD
./.
====================
Based/VBN
on/IN
their/PRP$
functional/JJ
categories/NNS
,/,
the/DT
transcription/NN
regulation-related/VBN
gene/NN
group/NN
,/,
which/WDT
included/VBD
four/CD
genes/NNS
related/JJ
to/TO
chromatin/NN
modification/NN
,/,
was/VBD
the/DT
most/JJS
common/JJ
gene/NN
group/NN
(/(
eight/CD
genes/NNS
)/)
./.
====================
This/DT
was/VBD
followed/VBN
by/IN
a/DT
group/NN
comprising/VBG
five/CD
genes/NNS
related/JJ
to/TO
transcription/NN
factor/signal/JJ
transduction/NN
./.
====================
Sanger/NN
sequencing/NN
====================
To/TO
confirm/VB
the/DT
25/CD
loci/NNS
,/,
we/PRP
tried/VBD
to/TO
amplify/VB
them/PRP
using/VBG
PCR/NN
analysis/NN
./.
====================
However/RB
,/,
only/RB
six/CD
loci/NNS
were/VBD
successfully/RB
amplified/VBN
in/IN
two/CD
samples/NNS
(/(
cases/NNS
Nos/NNS
./.
====================
1/CD
and/CC
5/CD
)/)
,/,
due/JJ
to/TO
severe/JJ
DNA/NN
damage/NN
in/IN
the/DT
FFPE/NN
samples/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
We/PRP
conducted/VBD
Sanger/NN
sequencing/NN
of/IN
the/DT
PCR/NN
products/NNS
./.
====================
Only/RB
one/CD
out/RP
of/IN
the/DT
six/CD
loci/NNS
was/VBD
authentic/JJ
;/:
one/CD
sample/NN
(/(
case/NN
No/DT
./.
====================
5/CD
)/)
contained/VBD
a/DT
missense/NN
mutation/NN
(/(
c.3592A/NN
>/JJR
T/NN
,/,
p.M1198L/NN
)/)
in/IN
the/DT
BCR/NN
gene/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
6/CD
)/)
./.
====================
To/TO
identify/VB
somatic/JJ
mutations/NNS
of/IN
NKTCL/NN
,/,
this/DT
study/NN
used/VBD
NGS/NN
technology/NN
,/,
which/WDT
revealed/VBD
25/CD
mutations/NNS
from/IN
21/CD
genes/NNS
in/IN
five/CD
cases/NNS
./.
====================
Three/CD
genes/NNS
were/VBD
classified/VBN
as/IN
the/DT
likely/JJ
actionable/JJ
group/NN
:/:
KMT2D/NN
,/,
ARID1A/NN
,/,
and/CC
TP53/NN
./.
====================
In/IN
particular/JJ
,/,
KMT2D/NN
,/,
also/RB
known/VBN
as/IN
MLL2/NN
,/,
showed/VBD
the/DT
same/JJ
variant/JJ
in/IN
four/CD
cases/NNS
./.
====================
Somatic/JJ
mutations/NNS
of/IN
KMT2D/NN
,/,
ARID1A/NN
,/,
and/CC
TP53/NN
in/IN
NKTCL/NN
were/VBD
recurrently/RB
reported/VBD
in/IN
recent/JJ
studies/NNS
using/VBG
NGS/NN
[/(
202122/CD
]/)
./.
====================
In/IN
these/DT
studies/NNS
,/,
KMT2D/NN
was/VBD
one/CD
of/IN
the/DT
most/JJS
frequently/RB
mutated/VBN
genes/NNS
,/,
together/RB
with/IN
STAT3/NN
,/,
BCOR/NN
,/,
DDX3X/NN
,/,
TP53/NN
,/,
and/CC
ARID1A/NN
./.
====================
These/DT
genes/NNS
were/VBD
suggested/VBN
as/IN
novel/JJ
driver/RB
genes/NNS
in/IN
the/DT
development/NN
of/IN
NKTCL/NN
./.
====================
We/PRP
could/MD
not/RB
identify/VB
the/DT
mutational/JJ
status/NN
of/IN
STAT3/NN
,/,
BCOR/NN
,/,
or/CC
DDX3X/NN
,/,
due/JJ
to/TO
the/DT
absence/NN
of/IN
these/DT
genes/NNS
from/IN
our/PRP$
cancer/NN
panel/NN
list/NN
./.
====================
The/DT
KMT2D/NN
gene/NN
encodes/VBZ
a/DT
histone/NN
methyltransferase/NN
,/,
is/VBZ
classified/VBN
in/IN
the/DT
chromatin/NN
modification/NN
group/NN
,/,
and/CC
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
regulating/VBG
gene/NN
transcription/NN
./.
====================
Somatic/JJ
mutations/NNS
in/IN
the/DT
KMT2D/NN
gene/NN
have/VBP
been/VBN
identified/VBN
in/IN
certain/JJ
cancers/NNS
[/(
2324/CD
]/)
./.
====================
Most/JJS
of/IN
these/DT
mutations/NNS
result/VBP
in/IN
an/DT
abnormally/RB
short/JJ
,/,
nonfunctional/JJ
histone/NN
methyltransferase/NN
that/DT
can/MD
not/RB
perform/VB
its/PRP$
role/NN
as/IN
a/DT
tumor/NN
suppressor/NN
,/,
resulting/VBG
in/IN
the/DT
development/NN
of/IN
cancer/NN
./.
====================
In/IN
one/CD
of/IN
the/DT
reports/NNS
described/VBN
above/IN
,/,
a/DT
loss-of-function/NN
mutation/NN
in/IN
KMT2D/NN
was/VBD
identified/VBN
by/IN
RNA/NN
sequencing/NN
./.
====================
The/DT
result/NN
supports/VBZ
the/DT
idea/NN
that/IN
KMT2D/NN
may/MD
be/VB
a/DT
tumor/NN
suppressor/NN
gene/NN
in/IN
the/DT
development/NN
of/IN
NKTCL/NN
and/CC
could/MD
be/VB
a/DT
potential/JJ
therapeutic/JJ
target/NN
./.
====================
Mutations/NNS
in/IN
this/DT
gene/NN
were/VBD
also/RB
found/VBD
in/IN
other/JJ
lymphomas/NNS
,/,
including/VBG
relapsed/JJ
diffuse/JJ
large/JJ
B-cell/NN
lymphoma/NN
,/,
mantle/NN
cell/NN
lymphoma/NN
,/,
and/CC
follicular/JJ
lymphoma/NN
[/(
252627/CD
]/)
./.
====================
In/IN
follicular/JJ
lymphoma/NN
,/,
an/DT
integrated/JJ
genomic/JJ
analysis/NN
identified/VBD
early/JJ
driver/RB
mutations/NNS
in/IN
the/DT
KMT2D/NN
gene/NN
,/,
together/RB
with/IN
other/JJ
chromatin/NN
regulator/NN
genes/NNS
./.
====================
Mutations/NNS
in/IN
the/DT
ARID1A/NN
gene/NN
have/VBP
been/VBN
found/VBN
in/IN
many/JJ
types/NNS
of/IN
cancers/NNS
,/,
including/VBG
ovarian/JJ
carcinoma/NN
,/,
gastric/JJ
carcinoma/NN
,/,
mantle/NN
cell/NN
lymphoma/NN
,/,
and/CC
pediatric/JJ
Burkitt/NN
lymphoma/NN
[/(
24262829/CD
]/)
./.
====================
We/PRP
identified/VBD
a/DT
mutation/NN
in/IN
ARID1A/NN
in/IN
one/CD
out/RP
of/IN
the/DT
five/CD
cases/NNS
./.
====================
The/DT
ARID1A/NN
gene/NN
encodes/VBZ
a/DT
protein/NN
that/WDT
forms/VBZ
one/CD
piece/NN
(/(
subunit/NN
)/)
of/IN
several/JJ
different/JJ
SWI/SNF/NN
protein/NN
complexes/NNS
./.
====================
SWI/SNF/NN
complexes/NNS
regulate/VBP
gene/NN
activity/NN
(/(
expression/NN
)/)
by/IN
a/DT
process/NN
known/VBN
as/IN
chromatin/NN
remodeling/NN
./.
====================
The/DT
mechanism/NN
by/IN
which/WDT
mutations/NNS
in/IN
the/DT
ARID1A/NN
gene/NN
contribute/VBP
to/TO
cancer/NN
is/VBZ
unknown/JJ
,/,
although/IN
it/PRP
is/VBZ
thought/VBN
that/DT
changes/NNS
in/IN
SWI/SNF/NN
complexes/NNS
are/VBP
involved/VBN
./.
====================
These/DT
changes/NNS
may/MD
disrupt/VB
the/DT
regulation/NN
of/IN
genes/NNS
that/WDT
help/VBP
control/NN
the/DT
growth/NN
and/CC
division/NN
of/IN
cells/NNS
,/,
which/WDT
lead/VBP
to/TO
cancer/NN
[/(
30/CD
]/)
./.
====================
TP53/NN
is/VBZ
a/DT
well-known/JJ
tumor/NN
suppressor/NN
gene/NN
./.
====================
The/DT
encoded/VBN
protein/NN
responds/VBZ
to/TO
diverse/JJ
cellular/JJ
stresses/NNS
to/TO
regulate/VB
the/DT
expression/NN
of/IN
target/NN
genes/NNS
,/,
thereby/RB
inducing/VBG
cell/NN
cycle/NN
arrest/NN
,/,
apoptosis/NN
,/,
senescence/NN
,/,
DNA/NN
repair/NN
,/,
or/CC
changes/NNS
in/IN
metabolism/NN
./.
====================
We/PRP
found/VBD
a/DT
mutation/NN
in/IN
TP53/NN
in/IN
one/CD
out/RP
of/IN
the/DT
five/CD
cases/NNS
./.
====================
Mutations/NNS
in/IN
TP53/NN
have/VBP
been/VBN
described/VBN
in/IN
NKTCL/NN
at/IN
various/JJ
proportions/NNS
,/,
suggesting/VBG
some/DT
racial/JJ
,/,
environmental/JJ
,/,
or/CC
lifestyle/JJ
differences/NNS
as/IN
a/DT
possible/JJ
cause/VBP
of/IN
tumorigenesis/NN
,/,
and/CC
appear/VBP
to/TO
correlate/VB
with/IN
more/RBR
advanced-stage/JJ
disease/NN
[/(
313233/CD
]/)
./.
====================
In/IN
other/JJ
lymphoma/NN
studies/NNS
using/VBG
NGS/NN
,/,
including/VBG
pediatric/JJ
Burkitt/NN
lymphoma/NN
and/CC
mantle/NN
cell/NN
lymphoma/NN
,/,
mutations/NNS
in/IN
TP53/NN
were/VBD
also/RB
frequently/RB
found/VBN
[/(
2629/CD
]/)
./.
====================
In/IN
summary/NN
,/,
the/DT
likely/JJ
actionable/JJ
group/NN
,/,
consisting/VBG
of/IN
KMT2D/NN
and/CC
ARID1A/NN
,/,
in/IN
addition/NN
to/TO
TP53/NN
,/,
seems/VBZ
to/TO
contain/VB
frequently/RB
mutated/VBN
tumor/NN
suppressor/NN
genes/NNS
in/IN
the/DT
development/NN
of/IN
NKTCL/NN
,/,
considering/VBG
their/PRP$
function/NN
and/CC
the/DT
previous/JJ
literature/NN
./.
====================
It/PRP
is/VBZ
likely/JJ
that/IN
other/JJ
genetic/JJ
changes/NNS
,/,
in/IN
addition/NN
to/TO
mutations/NNS
in/IN
these/DT
genes/NNS
,/,
are/VBP
necessary/JJ
for/IN
the/DT
development/NN
of/IN
this/DT
disease/NN
./.
====================
The/DT
other/JJ
genes/NNS
(/(
unknown/JJ
significance/NN
group/NN
)/)
showed/VBD
a/DT
varied/JJ
functional/JJ
spectrum/NN
./.
====================
Like/IN
the/DT
likely/JJ
actionable/JJ
group/NN
,/,
most/JJS
of/IN
these/DT
genes/NNS
may/MD
have/VB
a/DT
role/NN
as/IN
tumor/NN
suppressors/NNS
,/,
considering/VBG
their/PRP$
molecular/JJ
function/NN
:/:
chromatin/NN
modification/NN
(/(
SETD2/NN
and/CC
KAT6B/NN
)/)
,/,
transcriptional/JJ
regulator/NN
(/(
MBD1/NN
,/,
BCL11B/NN
,/,
ZNF521/NNP
,/,
and/CC
PER1/NN
)/)
,/,
regulation/NN
of/IN
cytokinesis/NN
and/CC
structural/JJ
integrity/NN
(/(
CDH11/NN
,/,
MYH9/NN
,/,
and/CC
SYNE1/NN
)/)
,/,
and/CC
DNA/NN
damage/NN
checkpoint/NN
(/(
ATR/NN
)/)
./.
====================
Additional/JJ
RNA/NN
sequencing/NN
could/MD
reveal/VB
the/DT
functional/JJ
status/NN
(/(
gene/NN
expression/NN
status/NN
)/)
of/IN
these/DT
genes/NNS
./.
====================
In/IN
contrast/NN
to/TO
the/DT
genes/NNS
described/VBN
above/IN
,/,
most/JJS
of/IN
the/DT
remaining/VBG
genes/NNS
might/MD
be/VB
related/JJ
to/TO
activating/VBG
mutations/NNS
./.
====================
The/DT
majority/NN
of/IN
these/DT
genes/NNS
is/VBZ
related/JJ
to/TO
transcription/NN
factors/NNS
and/CC
signal/NN
transduction/NN
(/(
ERG/NN
,/,
IKBKB/NN
,/,
FGFR1/NN
,/,
BCR/NN
,/,
and/CC
MYH11/NN
)/)
./.
====================
Other/JJ
genes/NNS
are/VBP
related/JJ
to/TO
angiogenesis/NN
(/(
FLT4/NN
and/CC
THBS1/NN
)/)
and/CC
RNA/NN
metabolism/NN
(/(
SBDS/NNS
)/)
./.
====================
In/IN
particular/JJ
,/,
ERG/NN
(/(
case/NN
No/DT
./.
====================
1/CD
)/)
,/,
MYH11/NN
(/(
case/NN
No/DT
./.
====================
2/CD
)/)
,/,
and/CC
BCR/NN
(/(
case/NN
No/DT
./.
====================
3/CD
)/)
showed/VBD
the/DT
highest/JJS
allele/NN
frequency/NN
in/IN
each/DT
case/NN
,/,
and/CC
BCR/NN
was/VBD
the/DT
only/RB
gene/NN
that/WDT
showed/VBD
a/DT
missense/NN
mutation/NN
result/NN
in/IN
Sanger/NN
sequencing/NN
./.
====================
But/CC
until/IN
now/RB
,/,
genetic/JJ
alterations/NNS
of/IN
these/DT
three/CD
genes/NNS
in/IN
NKTCL/NN
have/VBP
not/RB
been/VBN
described/VBN
,/,
and/CC
it/PRP
is/VBZ
difficult/JJ
to/TO
infer/VB
their/PRP$
molecular/JJ
function/NN
or/CC
impact/NN
in/IN
NKTCL/NN
,/,
considering/VBG
their/PRP$
known/JJ
function/NN
up/IN
to/TO
now/RB
./.
====================
As/IN
described/VBN
above/IN
,/,
this/DT
study/NN
did/VBD
not/RB
complete/JJ
Sanger/NN
sequencing/NN
validation/NN
due/JJ
to/TO
severe/JJ
DNA/NN
degradation/NN
of/IN
the/DT
FFPE/NN
samples/NNS
./.
====================
Although/IN
Sanger/NN
sequencing/NN
is/VBZ
still/RB
considered/VBN
the/DT
standard/JJ
technology/NN
for/IN
the/DT
validation/NN
of/IN
NGS/NN
,/,
it/PRP
has/VBZ
several/JJ
limitations/NNS
./.
====================
It/PRP
is/VBZ
insensitive/JJ
to/TO
alterations/NNS
that/IN
occur/VBP
at/IN
an/DT
allele/NN
frequency/NN
lower/JJR
than/IN
approximately/RB
20/CD
%/NN
[/(
34/CD
]/)
./.
====================
In/IN
cancer/NN
research/NN
,/,
histological/JJ
variables/NNS
,/,
such/JJ
as/IN
tumor/NN
purity/NN
,/,
tumor/NN
heterogeneity/NN
or/CC
subclonality/NN
,/,
and/CC
the/DT
ploidy/NN
of/IN
the/DT
tumor/NN
cells/NNS
,/,
within/IN
a/DT
sample/JJ
could/MD
significantly/RB
affect/VB
the/DT
sensitivity/NN
and/CC
specificity/NN
of/IN
DNA/NN
sequencing/NN
[/(
35/CD
]/)
./.
====================
However/RB
,/,
targeted/VBN
sequencing/NN
with/IN
very/RB
high/JJ
sequence/NN
coverage/VBP
,/,
like/IN
in/IN
this/DT
study/NN
,/,
allows/VBZ
for/IN
the/DT
detection/NN
of/IN
lower-abundance/JJ
(/(
low/JJ
allele/NN
frequency/NN
)/)
somatic/JJ
variants/NNS
and/CC
thus/RB
reveals/VBZ
clinically/RB
useful/JJ
information/NN
from/IN
stromally/RB
contaminated/JJ
or/CC
heterogeneous/JJ
tumor/NN
samples/NNS
[/(
36/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
allele/NN
frequency/NN
of/IN
the/DT
variants/NNS
ranged/VBD
from/IN
5.0/CD
%/NN
to/TO
27.1/CD
%/NN
,/,
and/CC
only/RB
three/CD
variants/NNS
showed/VBD
an/DT
allele/NN
frequency/NN
of/IN
over/IN
20/CD
%/NN
./.
====================
As/IN
a/DT
result/NN
,/,
Sanger/NN
sequencing/NN
was/VBD
not/RB
appropriate/JJ
for/IN
the/DT
validation/NN
of/IN
the/DT
mutations/NNS
in/IN
this/DT
study/NN
./.
====================
Because/IN
this/DT
study/NN
involved/VBD
only/RB
five/CD
cases/NNS
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
define/VB
their/PRP$
mutational/JJ
spectrum/NN
./.
====================
But/CC
,/,
the/DT
majority/NN
of/IN
the/DT
genes/NNS
could/MD
be/VB
grouped/VBN
as/IN
tumor/NN
suppressor/NN
genes/NNS
./.
====================
Previous/JJ
NKTCL/NN
studies/NNS
have/VBP
reported/VBN
some/DT
activating/VBG
mutations/NNS
[/(
37383940/CD
]/)
and/CC
deregulated/VBN
gene/NN
expression/NN
in/IN
various/JJ
oncogenic/JJ
pathways/NNS
[/(
414243/CD
]/)
./.
====================
This/DT
study/NN
revealed/VBD
no/DT
mutations/NNS
in/IN
oncogenes/NNS
that/IN
have/VBP
been/VBN
reported/VBN
in/IN
previous/JJ
mutation/NN
studies/NNS
or/CC
gene/NN
expression/NN
studies/NNS
in/IN
NKTCL/NN
./.
====================
However/RB
,/,
this/DT
study/NN
result/VBP
may/MD
imply/VB
that/IN
the/DT
mutations/NNS
of/IN
some/DT
tumor/NN
suppressor/NN
genes/NNS
and/CC
genes/NNS
involved/VBN
in/IN
transcriptional/JJ
regulation/NN
,/,
transcription/NN
factors/NNS
,/,
and/CC
signal/NN
transduction/NN
may/MD
have/VB
a/DT
role/NN
as/IN
a/DT
trigger/NN
,/,
resulting/VBG
in/IN
additional/JJ
oncogenic/JJ
events/NNS
in/IN
some/DT
pathways/NNS
and/CC
oncogenes/NNS
in/IN
the/DT
development/NN
of/IN
NKTCL/NN
and/CC
disease/NN
manifestation/NN
./.
====================
We/PRP
suggest/VBP
that/IN
these/DT
candidate/NN
genes/NNS
may/MD
be/VB
used/VBN
as/IN
potential/JJ
bio-markers/NNS
for/IN
this/DT
disease/NN
in/IN
the/DT
future/JJ
./.
====================
Further/RB
studies/NNS
of/IN
transcriptomic/JJ
alterations/NNS
and/CC
functional/JJ
analyses/NNS
could/MD
help/VB
identify/VBP
the/DT
molecular/JJ
function/NN
,/,
nature/NN
,/,
and/CC
clinical/JJ
significance/NN
of/IN
these/DT
candidate/NN
genes/NNS
in/IN
NKTCL/NN
and/CC
could/MD
accelerate/VB
the/DT
attainment/JJ
of/IN
the/DT
goal/NN
of/IN
personalized/VBN
medicine/JJ
based/VBN
on/IN
the/DT
genetic/JJ
alterations/NNS
in/IN
each/DT
patient/NN
./.
====================
Variant/JJ
filtering/VBG
step/NN
./.
====================
Final/JJ
22/CD
variants/NNS
====================
Variant/JJ
interpretation/NN
results/VBZ
====================
